These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36062772)

  • 1. Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy.
    Kim SH; Choi HS; Koo CM; Joo BR; Park BJ; Lee HK; Lee JS; Kim HD; Kang HC
    J Clin Neurol; 2022 Sep; 18(5):547-552. PubMed ID: 36062772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
    Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
    Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
    Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
    J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
    Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
    Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome.
    Iannone LF; Arena G; Battaglia D; Bisulli F; Bonanni P; Boni A; Canevini MP; Cantalupo G; Cesaroni E; Contin M; Coppola A; Cordelli DM; Cricchiuti G; De Giorgis V; De Leva MF; De Rinaldis M; d'Orsi G; Elia M; Galimberti CA; Morano A; Granata T; Guerrini R; Lodi MAM; La Neve A; Marchese F; Masnada S; Michelucci R; Nosadini M; Pilolli N; Pruna D; Ragona F; Rosati A; Santucci M; Spalice A; Pietrafusa N; Striano P; Tartara E; Tassi L; Papa A; Zucca C; Russo E; Mecarelli O;
    Front Neurol; 2021; 12():673135. PubMed ID: 34093420
    [No Abstract]   [Full Text] [Related]  

  • 12. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.
    Anderson CL; Evans V; Gorham L; Liu Z; Johnson CR; Carney PR
    Epilepsy Behav; 2021 Sep; 124():108325. PubMed ID: 34560358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
    Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
    Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
    Koo CM; Kim SH; Lee JS; Park BJ; Lee HK; Kim HD; Kang HC
    J Korean Med Sci; 2020 Dec; 35(50):e427. PubMed ID: 33372424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts' opinions using a nominal group technique (NGT) approach.
    Bonanni P; Ragona F; Fusco C; Gambardella A; Operto FF; Parmeggiani L; Sartori S; Specchio N
    Expert Opin Pharmacother; 2023 Apr; 24(5):655-663. PubMed ID: 37021712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Wijnen B; Armstrong N; Ramaekers B; Witlox W; Westwood M; Fayter D; Ryder S; Buksnys T; Worthy G; Misso K; Grimm S; Kleijnen J; Joore M
    Pharmacoeconomics; 2020 Oct; 38(10):1043-1053. PubMed ID: 32514751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
    Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
    Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.